Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment.

Thiolloy S, Edwards JR, Fingleton B, Rifkin DB, Matrisian LM, Lynch CC.

PLoS One. 2012;7(1):e29862. doi: 10.1371/journal.pone.0029862. Epub 2012 Jan 4.

2.

Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis.

Thiolloy S, Halpern J, Holt GE, Schwartz HS, Mundy GR, Matrisian LM, Lynch CC.

Cancer Res. 2009 Aug 15;69(16):6747-55. doi: 10.1158/0008-5472.CAN-08-3949.

3.

Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment.

Sato S, Futakuchi M, Ogawa K, Asamoto M, Nakao K, Asai K, Shirai T.

Cancer Sci. 2008 Feb;99(2):316-23. doi: 10.1111/j.1349-7006.2007.00690.x.

4.

Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth.

Mosig RA, Dowling O, DiFeo A, Ramirez MC, Parker IC, Abe E, Diouri J, Aqeel AA, Wylie JD, Oblander SA, Madri J, Bianco P, Apte SS, Zaidi M, Doty SB, Majeska RJ, Schaffler MB, Martignetti JA.

Hum Mol Genet. 2007 May 1;16(9):1113-23. Epub 2007 Mar 30.

5.

MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases.

Pivetta E, Scapolan M, Pecolo M, Wassermann B, Abu-Rumeileh I, Balestreri L, Borsatti E, Tripodo C, Colombatti A, Spessotto P.

Breast Cancer Res. 2011 Oct 27;13(5):R105. doi: 10.1186/bcr3047.

6.

Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.

Tauro M, Shay G, Sansil SS, Laghezza A, Tortorella P, Neuger AM, Soliman H, Lynch CC.

Mol Cancer Ther. 2017 Mar;16(3):494-505. doi: 10.1158/1535-7163.MCT-16-0315-T. Epub 2017 Jan 9.

7.

Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone.

Biswas S, Nyman JS, Alvarez J, Chakrabarti A, Ayres A, Sterling J, Edwards J, Rana T, Johnson R, Perrien DS, Lonning S, Shyr Y, Matrisian LM, Mundy GR.

PLoS One. 2011;6(11):e27090. doi: 10.1371/journal.pone.0027090. Epub 2011 Nov 11.

8.

Molecular mechanisms of tumor-bone interactions in osteolytic metastases.

Chirgwin JM, Guise TA.

Crit Rev Eukaryot Gene Expr. 2000;10(2):159-78. Review.

PMID:
11186331
9.

Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis.

Karsdal MA, Larsen L, Engsig MT, Lou H, Ferreras M, Lochter A, Delaissé JM, Foged NT.

J Biol Chem. 2002 Nov 15;277(46):44061-7. Epub 2002 Sep 10.

10.

Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis.

Lynch CC.

Bone. 2011 Jan;48(1):44-53. doi: 10.1016/j.bone.2010.06.007. Epub 2010 Jun 16. Review.

PMID:
20601294
11.

Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment.

Bruni-Cardoso A, Johnson LC, Vessella RL, Peterson TE, Lynch CC.

Mol Cancer Res. 2010 Apr;8(4):459-70. doi: 10.1158/1541-7786.MCR-09-0445. Epub 2010 Mar 23.

12.

Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment.

Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, Peng XH, Chirgwin JM, Guise TA.

PLoS One. 2009 Sep 3;4(9):e6896. doi: 10.1371/journal.pone.0006896.

13.

Advances in the biology of bone metastasis: how the skeleton affects tumor behavior.

Sterling JA, Edwards JR, Martin TJ, Mundy GR.

Bone. 2011 Jan;48(1):6-15. doi: 10.1016/j.bone.2010.07.015. Epub 2010 Jul 17. Review.

PMID:
20643235
14.

Microarray and proteomic analysis of breast cancer cell and osteoblast co-cultures: role of osteoblast matrix metalloproteinase (MMP)-13 in bone metastasis.

Morrison C, Mancini S, Cipollone J, Kappelhoff R, Roskelley C, Overall C.

J Biol Chem. 2011 Sep 30;286(39):34271-85. doi: 10.1074/jbc.M111.222513. Epub 2011 Jul 22.

15.

Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.

Shay G, Tauro M, Loiodice F, Tortorella P, Sullivan DM, Hazlehurst LA, Lynch CC.

Oncotarget. 2017 Jun 27;8(26):41827-41840. doi: 10.18632/oncotarget.18103.

16.

(Pre-)osteoclasts induce retraction of osteoblasts before their fusion to osteoclasts.

Perez-Amodio S, Beertsen W, Everts V.

J Bone Miner Res. 2004 Oct;19(10):1722-31. Epub 2004 May 17.

17.

Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.

Nannuru KC, Futakuchi M, Varney ML, Vincent TM, Marcusson EG, Singh RK.

Cancer Res. 2010 May 1;70(9):3494-504. doi: 10.1158/0008-5472.CAN-09-3251. Epub 2010 Apr 20.

18.

Transforming growth factor-beta in osteolytic breast cancer bone metastases.

Guise TA, Chirgwin JM.

Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S32-8. Review.

PMID:
14600590
19.

Parathyroid hormone-related protein and bone metastases.

Guise TA.

Cancer. 1997 Oct 15;80(8 Suppl):1572-80. Review.

PMID:
9362424
20.

Supplemental Content

Support Center